| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Credit > Credit Where Credit's Due |
|
Digg It - Credit Where Credit's Due
Borrowing money has become easier in recent years, and credit cards have become abundant and more and more According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product competitive. It seems to be so much easier to get hold of credit nowadays so it’s no surprise that there ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in is more debt in the developed countries than ever before. Credit card companies, banks and other lenders lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. all make their money on the interest they charge you for borrowing money from them. Obviously we can neve here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe predict in life when something is going to go pear shaped, we may lose our job for one reason or another, d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro we may have ill health and be unable to work, we may have other financial commitments and find that the mo ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ney we have doesn’t seem to stretch very far. This is unfortunate but quite often things can be resolved q easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ite soon with the least upset. People on lower incomes or poorer credit ratings are generally offered hig nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically her interest rates, and this is where many people come unstuck. Each month you have to make a payment, and and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ quite often people on low incomes will pay just the minimum balance from their credit card statement, now ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi his seems great for a while, until one day you realise that all you seem to be paying is interest! Your ba ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a lance is just not going down! So what do you do? Well some people starting weaving a very tangled web by t dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ansferring their balance to another card with a great introductory offer (if they are in the lucky positio cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin n to be accepted for another card). Again this seems fine for a while until the introductory offer expire tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen and you have to pay full whack interest! Meeting the monthly demands becomes quite difficult, and in the t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel end people are borrowing from one lender to pay another. This is where debt consolidation comes in. Basic ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ally, a lender will pay off all of your debts, and then you will pay just one bill, to them, they claim th y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products t they could even reduce some of your debt. Research is the best tool here, before you go off and sign up . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de with any old debt management company, read all of the terms and conditions and make sure you are aware of elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip hat is going on. Approached correctly debt management could avoid getting to the nasty stage of Bankruptcy tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Business Writing - Using Contractions Isn't a Bad Thing Project Outsourcing VS Temp Agencies When Starting A Business Consider The Barriers To Entry
|